The top US health insurance lobby, America’s Health Insurance Plans, threw its support behind New York Attorney General Eric Schneiderman and his antitrust case against Actavis.
The lawsuit alleges Actavis altered Namenda IL just enough to replace it with its newer formulation, Namenda IR, prior to its patent expiration. A judge ruled in a preliminary injunction in January that Actavis must keep Namenda IL on the market. AHIP submitted an amicus brief in support of the plaintiff at the end of February.
AHIP spokesperson Ben Jenkins stated in a news release at the time: “This case is an example of what happens when drugmakers engage in anticompetitive behavior under the guise of innovation…forcing a product switch to protect a monopoly punishes consumers in the worst possible way by delaying the entry of more affordable prescription drugs into the market.”
Full Content: Medical Marketing & Media
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI